(NASDAQ: RAPT) Rapt Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.
Rapt Therapeutics's earnings in 2025 is -$129,865,000.On average, 3 Wall Street analysts forecast RAPT's earnings for 2025 to be -$135,531,410, with the lowest RAPT earnings forecast at -$261,373,519, and the highest RAPT earnings forecast at -$44,882,322. On average, 3 Wall Street analysts forecast RAPT's earnings for 2026 to be -$119,690,591, with the lowest RAPT earnings forecast at -$207,250,720, and the highest RAPT earnings forecast at -$31,681,639.
In 2027, RAPT is forecast to generate -$143,227,408 in earnings, with the lowest earnings forecast at -$249,492,905 and the highest earnings forecast at -$36,961,912.